Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Drugs Dermatol ; 18(4): 394-396, 2019 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-31017383

RESUMEN

Copy: A number of biologics have been approved for use in plaque-type psoriasis. They act by either blocking the action of a specific type of cell or protein in the immune system. Case presentation: Herein, we report a case of a 46-year-old woman with a 12-year history of severe plaque psoriasis and psoriatic arthritis who was treated successfully with guselkumab and adalimumab after failure of prior topical corticosteroids, cyclosporine and narrow-band ultraviolet B (NBUVB) phototherapy. Conclusion: There is limited data supporting the combination of biological agents in the management of psoriasis and psoriatic arthritis. This is the first case report of plaque psoriasis with arthritis, successfully treated with guselkumab and adalimumab combination therapy, without concurrent use of other systemic agents during the treatment. However, further studies need to be carried out to evaluate the efficacy and safety of this biologic combination therapy. J Drugs Dermatol. 2019;18(4):394-396.


Asunto(s)
Adalimumab/administración & dosificación , Anticuerpos Monoclonales/administración & dosificación , Productos Biológicos/administración & dosificación , Psoriasis/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados , Esquema de Medicación , Resistencia a Medicamentos , Quimioterapia Combinada/métodos , Femenino , Humanos , Inyecciones Subcutáneas , Persona de Mediana Edad , Psoriasis/diagnóstico , Psoriasis/patología , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA